Why the study?
Does MANP administered once subcutaneously improve safety, tolerability, and cyclic guanosine monophosphate activation in patients with hypertension and metabolic syndrome?
Does MANP administered once subcutaneously improve safety, tolerability, and cyclic guanosine monophosphate activation in patients with hypertension and metabolic syndrome?
Answers are grounded in this paper and cite their sources.
A single subcutaneous injection of MANP appears well-tolerated in patients with metabolic syndrome, showing early indications of blood pressure lowering and beneficial effects on glucose metabolism.
No abstract yet. The journal hasn't published one we can show.
No takes yet. Share an insight, caveat, or question.
Goetze et al. (2024) conducted an editorial in Hypertension and metabolic syndrome (n=22). MANP (modified form of atrial natriuretic peptide) vs. Placebo was evaluated on Safety, tolerability, and cyclic guanosine monophosphate activation.
Synapse has enriched 10 related papers. Consider them for comparative context: